Peter Houghton J. PhD

Peter Houghton J. PhD
ProfessorCollege of MedicinePeter.Houghton@nationwidechildrens.org
Children's Hospital 700 Children's Drive Columbus OH 43205
Phone:(614) 355-2670Fax:
  • Administrative
  • Translational Therapeutics

Research Description

The Houghton Lab is focused on understanding the basic biology of childhood solid tumors, largely sarcoma. Dr. Houghton has identified a chromosomal rearrangement in rhabdomyosarcoma that leads to downstream over-expression of insulin-like growth factor 2 (IGF2) ligand. His lab is working to interpret the signaling pathway and is developing therapeutic approaches to block IGF signaling in rhabdomyosarcoma, Wilms’ tumors, neuroblastoma, Ewing sarcomas, and a range of other tumors.

Current Publications

  • Kolb EA, Gorlick R, Billups CA, Hawthorne T, Kurmasheva RT, Houghton PJ, Smith MAInitial testing (stage 1) of glembatumumab vedotin (CDX-011) by the pediatric preclinical testing program.Pediatr Blood Cancer 61 1816-21 10/1/2014
  • Adamson PC, Houghton PJ, Perilongo G, Pritchard-Jones KDrug discovery in paediatric oncology: roadblocks to progress.Nat Rev Clin Oncol in press 9/16/2014
  • Carol H, Fan MM, Harasym TO, Boehm I, Mayer LD, Houghton P, Smith MA, Lock RBEfficacy of CPX-351, (cytarabine:daunorubicin) liposome injection, against acute lymphoblastic leukemia (ALL) xenograft models of the Pediatric Preclinical Testing Program.Pediatr Blood Cancer in press 9/9/2014
  • Kishore N, Binneman B, Mahapatra A, van de Venter M, du Plessis-Stoman D, Boukes G, Houghton P, Marion Meyer JJ, Lall NCytotoxicity of synthesized 1,4-naphthoquinone analogues on selected human cancer cell lines.Bioorg Med Chem 22 5013-9 9/1/2014
  • Suryani S, Carol H, Chonghaile TN, Frismantas V, Sarmah C, High L, Bornhauser B, Cowley MJ, Szymanska B, Evans K, Boehm I, Tonna E, Jones L, Manesh DM, Kurmasheva RT, Billups C, Kaplan W, Letai A, Bourquin JP, Houghton PJ, Smith MA, Lock RBCell and Molecular Determinants of In Vivo Efficacy of the BH3 Mimetic ABT-263 against Pediatric Acute Lymphoblastic Leukemia Xenografts.Clin Cancer Res 20 4520-31 9/1/2014
  • Smith MA, Houghton PJ, Kurmasheva RT, Lyalin D, Maris JM, Kolb EA, Gorlick R, Reynolds CP, Kang MH, Keir ST, Wu JInitial solid tumor testing (Stage 1) of AZD1480, an inhibitor of Janus kinases 1 and 2 by the pediatric preclinical testing program.Pediatr Blood Cancer in press 8/17/2014
  • Seibel NL, Smith M, Uren A, Patel SR, Trent J, Savage SA, Mirabello L, Reinke D, Barkaukas DA, Krailo M, Bernstein M, Khanna C, Fan TM, Gorlick R, Helman LJ, Kleinerman ES, Adamson PC, Houghton PJ, Tap WD, Welch DR, Steeg PS, Merlino G, Sorensen PH, Meltzer P, Kirsch DG, Janeway KA, Weigel B, Randall L, Withrow SJ, Paoloni M, Kaplan R, Teicher BAToward a drug development path that targets metastatic progression in osteosarcoma.Clin Cancer Res 20 4200-9 8/15/2014
  • Carol H, Maris JM, Kang MH, Reynolds CP, Kolb EA, Gorlick R, Keir ST, Wu J, Kurmasheva RT, Houghton PJ, Smith MA, Lock RB, Lyalin DInitial testing (stage 1) of the notch inhibitor PF-03084014, by the pediatric preclinical testing program.Pediatr Blood Cancer 61 1493-6 8/1/2014
  • Kang MH, Reynolds CP, Maris JM, Gorlick R, Kolb EA, Lock R, Carol H, Keir ST, Wu J, Lyalin D, Kurmasheva RT, Houghton PJ, Smith MAInitial testing (stage 1) of the investigational mTOR kinase inhibitor MLN0128 by the pediatric preclinical testing program.Pediatr Blood Cancer 61 1486-9 8/1/2014
  • Fouladi M, Perentesis JP, Phillips CL, Leary S, Reid JM, McGovern RM, Ingle AM, Ahern CH, Ames MM, Houghton P, Doyle LA, Weigel B, Blaney SMA phase I trial of MK-2206 in children with refractory malignancies: a Children's Oncology Group study.Pediatr Blood Cancer 61 1246-51 7/1/2014
  • Kurmasheva RT, Reynolds CP, Kang MH, Allievi C, Houghton PJ, Smith MAInitial testing (stage 1) of the topoisomerase II inhibitor pixantrone, by the pediatric preclinical testing program.Pediatr Blood Cancer 61 922-4 5/1/2014
  • Flucke UE, Houghton PJ, Oyen WJ, Boerman OC, van der Graaf WT, Fleuren ED, Versleijen-Jonkers YM, Roeffen MH, Franssen GMTemsirolimus combined with cisplatin or bevacizumab is active in osteosarcoma models.Int J Cancer in press 4/26/2014
  • Selvendiran K, Rath KS, Naidu SK, Lata P, Bid HK, Rivera BK, McCann GA, Tierney BJ, Elnaggar AC, Bravo V, Leone G, Houghton P, Hideg K, Kuppusamy P, Cohn DEHO-3867, a safe STAT3 inhibitor, is selectively cytotoxic to ovarian cancer.Cancer Res 74 2316-27 4/15/2014
  • Xiao L, Zambetti GP, Houghton PJ, Cam H, Cam M, Bid HKp53/TAp63 and AKT regulate mammalian target of rapamycin complex 1 (mTORC1) signaling through two independent parallel pathways in the presence of DNA damage.J Biol Chem 289 4083-94 2/14/2014
  • Houghton PJ, Kurmasheva RT, Kolb EA, Wu J, Gorlick R, Maris JM, Smith MAInitial testing (Stage 1) of TAK-701, a humanized hepatocyte growth factor binding antibody, by the Pediatric Preclinical Testing Program.Pediatr Blood Cancer 61 380-2 2/1/2014
  • Carol H, Gorlick R, Kolb EA, Morton CL, Manesh DM, Keir ST, Reynolds CP, Kang MH, Maris JM, Wozniak A, Hickson I, Lyalin D, Kurmasheva RT, Houghton PJ, Smith MA, Lock RInitial testing (stage 1) of the histone deacetylase inhibitor, quisinostat (JNJ-26481585), by the Pediatric Preclinical Testing Program.Pediatr Blood Cancer 61 245-52 2/1/2014
  • Pierson CR, Powell K, Bratasz A, Raffel C, Studebaker AW, Hutzen B, Bid HK, Houghton PJTreatment of medulloblastoma with oncolytic measles viruses expressing the angiogenesis inhibitors endostatin and angiostatin.BMC Cancer 14 206 1/1/2014
  • Bid HK, Roberts RD, Cam M, Audino A, Kurmasheva RT, Lin J, Houghton PJ, Cam HΔNp63 promotes pediatric neuroblastoma and osteosarcoma by regulating tumor angiogenesis.Cancer Res 74 320-9 1/1/2014
  • Cao Y, Roth M, Piperdi S, Montoya K, Sowers R, Rao P, Geller D, Houghton P, Kolb EA, Gill J, Gorlick RInsulin-Like Growth Factor 1 Receptor and Response to Anti-IGF1R Antibody Therapy in Osteosarcoma.PLoS One 9 e106249 1/1/2014
  • Gorlick R, Kolb EA, Keir ST, Maris JM, Reynolds CP, Kang MH, Carol H, Lock R, Billups CA, Kurmasheva RT, Houghton PJ, Smith MAInitial testing (stage 1) of the Polo-like kinase inhibitor volasertib (BI 6727), by the Pediatric Preclinical Testing Program.Pediatr Blood Cancer 61 158-64 1/1/2014
  • Bid HK, Kibler A, Phelps DA, Manap S, Xiao L, Lin J, Capper D, Oswald D, Geier B, DeWire M, Smith PD, Kurmasheva RT, Mo X, Fernandez S, Houghton PJDevelopment, characterization, and reversal of acquired resistance to the MEK1 inhibitor selumetinib (AZD6244) in an in vivo model of childhood astrocytoma.Clin Cancer Res 19 6716-29 12/15/2013
  • Hsu SH, Wang B, Kutay H, Bid H, Shreve J, Zhang X, Costinean S, Bratasz A, Houghton P, Ghoshal KHepatic loss of miR-122 predisposes mice to hepatobiliary cyst and hepatocellular carcinoma upon diethylnitrosamine exposure.Am J Pathol 183 1719-30 12/1/2013
  • Wood AC, Maris JM, Gorlick R, Kolb EA, Keir ST, Reynolds CP, Kang MH, Wu J, Kurmasheva RT, Whiteman K, Houghton PJ, Smith MAInitial testing (Stage 1) of the antibody-maytansinoid conjugate, IMGN901 (Lorvotuzumab mertansine), by the pediatric preclinical testing program.Pediatr Blood Cancer 60 1860-7 11/1/2013
  • Houghton PJNew insights into drug development for pediatric solid tumors: what preclinical data justify clinical trials in pediatric cancer?Expert Rev Anticancer Ther 13 1135-8 10/1/2013
  • Bid HK, Roberts RD, Manchanda PK, Houghton PJRAC1: an emerging therapeutic option for targeting cancer angiogenesis and metastasis.Mol Cancer Ther 12 1925-34 10/1/2013
  • Kolb EA, Gorlick R, Reynolds CP, Kang MH, Carol H, Lock R, Keir ST, Maris JM, Billups CA, Desjardins C, Kurmasheva RT, Houghton PJ, Smith MAInitial testing (stage 1) of eribulin, a novel tubulin binding agent, by the pediatric preclinical testing program.Pediatr Blood Cancer 60 1325-32 8/1/2013
  • Balkhi MY, Iwenofu OH, Bakkar N, Ladner KJ, Chandler DS, Houghton PJ, London CA, Kraybill W, Perrotti D, Croce CM, Keller C, Guttridge DCmiR-29 acts as a decoy in sarcomas to protect the tumor suppressor A20 mRNA from degradation by HuR.Sci Signal 6 ra63 7/30/2013
  • Shen C, Houghton PJThe mTOR pathway negatively controls ATM by up-regulating miRNAs.Proc Natl Acad Sci U S A 110 11869-74 7/16/2013
  • Lock RB, Carol H, Maris JM, Kang MH, Reynolds CP, Kolb EA, Gorlick R, Keir ST, Billups CA, Kurmasheva RT, Houghton PJ, Smith MAInitial testing (stage 1) of ganetespib, an Hsp90 inhibitor, by the Pediatric Preclinical Testing Program.Pediatr Blood Cancer 60 E42-5 7/1/2013
  • Smith MA, Houghton PA proposal regarding reporting of in vitro testing results.Clin Cancer Res 19 2828-33 6/1/2013
  • Shen C, Oswald D, Phelps D, Cam H, Pelloski CE, Pang Q, Houghton PJRegulation of FANCD2 by the mTOR pathway contributes to the resistance of cancer cells to DNA double-strand breaks.Cancer Res 73 3393-401 6/1/2013
  • Bid HK, London CA, Gao J, Zhong H, Hollingsworth RE, Fernandez S, Mo X, Houghton PJDual targeting of the type 1 insulin-like growth factor receptor and its ligands as an effective antiangiogenic strategy.Clin Cancer Res 19 2984-94 6/1/2013
  • Smith MA, Reynolds CP, Kang MH, Carol H, Lock R, Gorlick R, Kolb EA, Kurmasheva RT, Keir ST, Maris JM, Billups CA, Houghton PJInitial testing (stage 1) of the phosphatidylinositol 3' kinase inhibitor, SAR245408 (XL147) by the pediatric preclinical testing program.Pediatr Blood Cancer 60 791-8 5/1/2013
  • Keir ST, Maris JM, Reynolds CP, Kang MH, Kolb EA, Gorlick R, Lock R, Carol H, Morton CL, Wu J, Kurmasheva RT, Houghton PJ, Smith MAInitial testing (stage 1) of temozolomide by the pediatric preclinical testing program.Pediatr Blood Cancer 60 783-90 5/1/2013
  • Lock RB, Carol H, Szymanska B, Evans K, Boehm I, Houghton PJ, Smith MAThe anti-CD19 antibody-drug conjugate SAR3419 prevents hematolymphoid relapse postinduction therapy in preclinical models of pediatric acute lymphoblastic leukemia.Clin Cancer Res 19 1795-805 4/1/2013
  • Reynolds CP, Kang MH, Keir ST, Maris JM, Gorlick R, Kolb EA, Billups CA, Geier B, Kurmasheva RT, Houghton PJ, Smith MA, Lock RB, Carol HInitial testing of the MDM2 inhibitor RG7112 by the Pediatric Preclinical Testing Program.Pediatr Blood Cancer 60 633-41 4/1/2013
  • McHugh K, Li N, Chronowski C, Sebastian N, Singh M, Kurmasheva R, Houghton P, Pelloski CE, Kaplon R, Hadziahmetovic M, Sommerfeld J, Bondra K, Lu L, Leasure J, Nguyen PThe application of radiation therapy to the Pediatric Preclinical Testing Program (PPTP): results of a pilot study in rhabdomyosarcoma.Pediatr Blood Cancer 60 377-82 3/1/2013
  • Smith MA, Gorlick R, Kolb EA, Houghton PJ, Morton CL, Neale G, Keir ST, Carol H, Lock R, Phelps D, Kang MH, Reynolds CP, Maris JM, Billups CInitial testing (stage 1) of the cyclin dependent kinase inhibitor SCH 727965 (dinaciclib) by the pediatric preclinical testing program.Pediatr Blood Cancer 59 1266-74 12/15/2012
  • Reynolds CP, Houghton PJ, Alexander D, Kolb EA, Gorlick R, Keir ST, Carol H, Lock R, Billups CA, Smith MA, Batra V, Maris JM, Kang MHInitial testing (stage 1) of SGI-1776, a PIM1 kinase inhibitor, by the pediatric preclinical testing program.Pediatr Blood Cancer 59 749-52 10/1/2012
  • Smith MA, Kang MH, Reynolds CP, Kurmasheva RT, Alexander D, Billups CA, Toretsky JA, Houghton PJEvaluation of arsenic trioxide by the pediatric preclinical testing program with a focus on Ewing sarcoma.Pediatr Blood Cancer 59 753-5 10/1/2012

The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC – James) 300 W. 10th Ave. Columbus, OH 43210 Phone: 1-800-293-5066 | Email: jamesline@osumc.edu